Endocrine pancreas engineered using porcine islets and partial pancreatic scaffolds
Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved..
OBJECTIVES: Because therapeutic options for severe diabetes are currently limited, there is a continuing need for new therapeutic strategies, especially in the field of regenerative medicine. Collaborative efforts across the fields of tissue engineering technology and islet biology may be able to create functionally engineered islets capable of restoring endocrine function in patients with insulin-dependent diabetes.
METHODS: This engineered scaffold was seeded with isolated primary porcine islets via the pancreatic duct using a multi-step infusion technique. Endocrine function of perfusion-cultured islets in the native scaffold was analyzed by immunohistochemical staining of insulin and glucagon as well as by the insulin stimulation test.
RESULTS: The pancreas in this large animal could be uniformly decellularized by perfusion with trypsin and TritonX-100 via the pancreatic duct, as shown by positive staining of extracellular matrix (ECM) components. These scaffolds derived from porcine pancreas were able to maintain the cellular integrity of islets that had repopulated the parenchymal space, which is fundamental for the restoration of endocrine function. Insulin release up to four days after islet infusion was maintained.
CONCLUSIONS: This scaffold from a large animal maintained islet survival and function in the short-term, retaining the cells as a solid organ in the parenchymal space after infusion through the pancreatic duct. These results suggest that this scaffold is suitable for further fabrication of fully functional bioengineered endocrine pancreases when implanted in vivo. Therefore, it may represent a key improvement in the field of beta-cell replacement therapy. Nonetheless, the facilitation of longer-term islet survival and studies of implantation in vivo is required for successful clinical translation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. - 16(2016), 5 vom: 28. Sept., Seite 922-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katsuki, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell transplantation |
|---|
| Anmerkungen: |
Date Completed 27.03.2017 Date Revised 27.03.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pan.2016.06.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM261817191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261817191 | ||
| 003 | DE-627 | ||
| 005 | 20231224200400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pan.2016.06.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0872.xml |
| 035 | |a (DE-627)NLM261817191 | ||
| 035 | |a (NLM)27350058 | ||
| 035 | |a (PII)S1424-3903(16)30482-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katsuki, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endocrine pancreas engineered using porcine islets and partial pancreatic scaffolds |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2017 | ||
| 500 | |a Date Revised 27.03.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: Because therapeutic options for severe diabetes are currently limited, there is a continuing need for new therapeutic strategies, especially in the field of regenerative medicine. Collaborative efforts across the fields of tissue engineering technology and islet biology may be able to create functionally engineered islets capable of restoring endocrine function in patients with insulin-dependent diabetes | ||
| 520 | |a METHODS: This engineered scaffold was seeded with isolated primary porcine islets via the pancreatic duct using a multi-step infusion technique. Endocrine function of perfusion-cultured islets in the native scaffold was analyzed by immunohistochemical staining of insulin and glucagon as well as by the insulin stimulation test | ||
| 520 | |a RESULTS: The pancreas in this large animal could be uniformly decellularized by perfusion with trypsin and TritonX-100 via the pancreatic duct, as shown by positive staining of extracellular matrix (ECM) components. These scaffolds derived from porcine pancreas were able to maintain the cellular integrity of islets that had repopulated the parenchymal space, which is fundamental for the restoration of endocrine function. Insulin release up to four days after islet infusion was maintained | ||
| 520 | |a CONCLUSIONS: This scaffold from a large animal maintained islet survival and function in the short-term, retaining the cells as a solid organ in the parenchymal space after infusion through the pancreatic duct. These results suggest that this scaffold is suitable for further fabrication of fully functional bioengineered endocrine pancreases when implanted in vivo. Therefore, it may represent a key improvement in the field of beta-cell replacement therapy. Nonetheless, the facilitation of longer-term islet survival and studies of implantation in vivo is required for successful clinical translation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell transplantation | |
| 650 | 4 | |a Extracellular matrix | |
| 650 | 4 | |a Large animal | |
| 650 | 4 | |a Recellularization | |
| 650 | 4 | |a Tissue engineering | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Yagi, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Okitsu, Teru |e verfasserin |4 aut | |
| 700 | 1 | |a Kitago, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Tajima, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kadota, Yoshie |e verfasserin |4 aut | |
| 700 | 1 | |a Hibi, Taizo |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Itano, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Shoji |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Yuko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. |d 2001 |g 16(2016), 5 vom: 28. Sept., Seite 922-30 |w (DE-627)NLM119887509 |x 1424-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2016 |g number:5 |g day:28 |g month:09 |g pages:922-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pan.2016.06.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2016 |e 5 |b 28 |c 09 |h 922-30 | ||